VOXZOGO DIN 02564661
Health Canada record
| Active ingredient(s) | VOSORITIDE 0.56 MG |
|---|---|
| Dosage form | Powder For Solution |
| Route | Subcutaneous |
| Schedule | SCHEDULE D; PRESCRIPTION |
| Class | Human |
| ATC | M05BX07 VOSORITIDE |
| Original market date | 05-May-2026 |
| Current status date | 05-May-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
BioMarin International Limited — licence , not currently licensed, last inspection rating C (2024-02-16).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing VOSORITIDE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02564653 | VOXZOGO | BIOMARIN INTERNATIONAL LIMITED | Powder For Solution | VOSORITIDE 0.4 MG | Marketed |
| 02564688 | VOXZOGO | BIOMARIN INTERNATIONAL LIMITED | Powder For Solution | VOSORITIDE 1.2 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36762 | 2026-01-21 | New Drug Submission (NDS) |
International API supply for VOSORITIDE
1 active FDA Drug Master Files.
Request a quote for VOXZOGO